EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era

Takuya Fukushima, Hidehiro Itonaga iD, Hikaru Sakamoto, Wataru Takeda, Masahito Tokunaga, Takeharu Kato, Takuro Kuriyama, Toshiro Kawakita, Machiko Fujioka, Yasuhiko Miyazaki, Naoyuki Uchida, Yasuo Mori iD und 11 weitere

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70070 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Takuya Fukushima und 22 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus…. Hauptthemen laut MEDLINE: Cytomegalovirus, Leukemia-Lymphoma, Adult T-Cell, Cytomegalovirus Infections, Virus Activation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Takeda Science Foundation, Nagasaki-ken Medical Association, Grant-in-Aid for Scientific Research (KAKENHI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus reactivation (CMV‐react) is an indicator for the worse non‐relapse mortality (NRM) and overall survival (OS) after allogeneic hematopoietic stem cell transplantation using HLA‐matched related donor (MRD) and unrelated donor (URD) for adult T‐cell leukemia/lymphoma (ATL). However, it remains unclear whether CMV‐react correlates with outcomes after unrelated cord blood (U‐CB) transplantation.

Methods

We conducted a retrospective nationwide study to evaluate the impact of CMV‐react on the outcomes after posttransplant 100 days. Data were collected from 205, 461, and 268 patients who used MRD, URD, and U‐CB, respectively, between 2001 and 2022 and survived without relapse for over 100 days after transplantation.

Results

In multivariate analyses, CMV‐react correlated with worse OS in the MRD (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.02–2.39; p = 0.04) and URD groups (HR, 1.45; 95% CI, 1.00–2.09; p = 0.05), but not in the U‐CB group (HR, 1.34; 95% CI, 0.88–2.03; p = 0.2). CMV‐react correlated with higher NRM in the MRD (HR, 1.79; 95% CI, 1.01–3.16; p = 0.05) and URD groups (HR, 1.68; 95% CI, 1.01–2.82; p = 0.05), but not in the U‐CB group (HR, 1.16; 95% CI, 0.62–2.19; p = 0.6). CMV‐react did not correlate with the incidence of relapse in any group.

Conclusion

CMV‐react was not associated with the outcomes in the U‐CB group, while CMV‐react correlates with worse OS and NRM in the MRD and URD groups, indicating the need for a more intensive strategy for late‐phase complications in U‐CB transplantation for ATL with and without CMV‐react.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusLeukemia-Lymphoma, Adult T-CellCytomegalovirus InfectionsVirus ActivationCord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationHumansMaleFemaleRetrospective StudiesAdultMiddle AgedPrognosisTransplantation, HomologousAntiviral AgentsUnrelated DonorsAgedYoung AdultAcetatesQuinazolines

Stichwörter der Autor:innen

adult T‐cell leukemia/lymphomaallogeneic hematopoietic stem cell transplantationcytomegalovirus

Substanzen

Antiviral AgentsletermovirAcetatesQuinazolines

Autor:innen und Institutionen

  • Laboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.

ORCID-Profile: Hidehiro Itonaga, Yasuo Mori, Hirohisa Nakamae, Masao Ogata, Yoshinobu Kanda, Shigeo Fuji

Förderung

  • Takeda Science Foundation
  • Nagasaki-ken Medical Association
  • Grant-in-Aid for Scientific Research (KAKENHI)
  • Japan Society for the Promotion of Science

Zitieren

APA

Fukushima, T., Itonaga, H., Sakamoto, H., Takeda, W., Tokunaga, M., Kato, T., Kuriyama, T., Kawakita, T., Fujioka, M., Miyazaki, Y., Uchida, N., Mori, Y., Nakamae, H., Ogata, M., Imada, K., Onizuka, M., Morichika, K., Kanda, Y., Fukuda, T., …, & ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy (2025). Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era. Transplant Infectious Disease. https://doi.org/10.1111/tid.70070

Vancouver

Fukushima T, Itonaga H, Sakamoto H, Takeda W, Tokunaga M, Kato T, et al. Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era. Transplant Infectious Disease. 2025. doi:10.1111/tid.70070

BibTeX
@article{Fukushima2025,
  author = {Fukushima, Takuya and Itonaga, Hidehiro and Sakamoto, Hikaru and Takeda, Wataru and Tokunaga, Masahito and Kato, Takeharu and Kuriyama, Takuro and Kawakita, Toshiro and Fujioka, Machiko and Miyazaki, Yasuhiko and Uchida, Naoyuki and Mori, Yasuo and Nakamae, Hirohisa and Ogata, Masao and Imada, Kazunori and Onizuka, Makoto and Morichika, Kazuho and Kanda, Yoshinobu and Fukuda, Takahiro and Atsuta, Yoshiko and Fuji, Shigeo and Yoshimitsu, Makoto and ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy, ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy},
  title = {Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T‐Cell Leukemia/Lymphoma in the Pre‐Letermovir Era},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70070}
}
Kostenlos starten →